Table 3.
Summary of data from randomized placebo-controlled clinical trials investigating the effect of pharmacotherapy on mortality in COPD patients
| Source of data | Comparison | RRa (95% CI) of mortality | Statistical significance |
|---|---|---|---|
| Clinical trials for ICS | |||
| (Burge et al 2000) | FP vs placebo | 0.77 (0.54, 1.11) | NS |
| (Van Der Valk et al 2002) | FP vs placebo | 0.98 (0.06, 15.55) | NS |
| (Lung Health Study Research Group 2000) | Triamcinolone vs placebo | 0.79 (0.40, 1.53) | NS |
| (Vestbo et al 1999) | Budesonide vs placebo | 0.80 (0.22, 2.92) | NS |
| (Pauwels et al 1999) | Budesonide vs placebo | 0.81 (0.22, 2.04) | NS |
| Pooled summary (n=3678) (Sin et al 2003) | ICS vs placebo | 0.78 (0.58, 1.05) | NS |
| Pooled summary (n=5085)(Sin et al 2005) | ICS vs placebo | 0.73 (0.55, 0.96) | Significant |
| Clinical trials for LABA + ICS | |||
| (Szafranski et al 2003) | Budesonide+formoterol vs placebo | 0.66 (0.24, 1.81) | NS |
| (Mahler et al 2002) | FP+salmeterol vs placebo | 0.16 (0.01, 3.01) | NS |
| Pooled summary (n=1486) (Sin et al 2003) | ICS+LABA vs placebo | 0.52 (0.20, 1.34) | NS |
a
Hazard ratio.
Abbreviations: CI, confidence interval; FP, fluticasone propionate; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; NS, not significant; RR, relative risk.